Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem

Bibliographic Details
Main Authors:	Natalia G. Vallianou, Gerasimos Socrates Christodoulatos, Dimitris Kounatidis, Maria Dalamaga
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Metabolism Open
Subjects:	Cardiovascular disease Diabetes Heart failure Sodium glucose co-transporters inhibitor Sotagliflozin
Online Access:	http://www.sciencedirect.com/science/article/pii/S258993682100013X

Similar Items

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01)

Sodium–glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction
by: Adamo, M., et al.
Published: (2022)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
by: Chiara Maria Assunta Cefalo, et al.
Published: (2019-02-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes
by: Juan José Rodríguez, et al.
Published: (2018-01-01)

Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
by: Diego Chambergo-Michilot, et al.
Published: (2021-02-01)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
by: Giuseppe Palmiero, et al.
Published: (2021-05-01)

SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
by: Yoshifumi Saisho
Published: (2020-05-01)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
by: Bonora BM, et al.
Published: (2020-01-01)

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
by: Yuling Yan, et al.
Published: (2021-06-01)

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload
by: Sophia L. Young, et al.
Published: (2021-09-01)

Falls and SGLT-2 inhibitors in geriatric patients—A case report
by: Anil Tasdemir, et al.
Published: (2020-01-01)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
by: Lisanne C. A. Smidt, et al.
Published: (2021-09-01)

Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure
by: Alex Ali Sayour, et al.
Published: (2021-07-01)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
by: Benedetta Maria Bonora, et al.
Published: (2019-08-01)

Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
by: Vicente Martínez-Vizcaíno, et al.
Published: (2021-06-01)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019-04-01)

SGLT2i: beyond the glucose-lowering effect
by: Lihua Ni, et al.
Published: (2020-06-01)

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
by: Anastasios Tentolouris, et al.
Published: (2019-08-01)

Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
by: Walter Masson, et al.
Published: (2021-08-01)

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
by: Berra, C.C, et al.
Published: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
by: Adel E. Berbari
Published: (2020-12-01)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
by: Gloria M. Gager, et al.
Published: (2021-07-01)

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
by: Hung-Yi Chen, et al.
Published: (2020-06-01)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
by: Swetha R. Kanduri, et al.
Published: (2020-08-01)

Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
by: Gloria M. Gager, et al.
Published: (2021-11-01)

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
by: J. Karalliedde
Published: (2021-04-01)

Class effect for SGLT-2 inhibitors: a tale of 9 drugs
by: Dario Giugliano, et al.
Published: (2019-07-01)

Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment
by: Siqi Wang, et al.
Published: (2021-07-01)

Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
by: Wayne Huey-Herng Sheu, et al.
Published: (2020-02-01)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
by: Chu Lin, et al.
Published: (2021-04-01)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
by: Yan-Ting Lu, et al.
Published: (2018-11-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Deng Pan, et al.
Published: (2021-06-01)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
by: Daiji Kawanami, et al.
Published: (2017-05-01)

Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling
by: Lindsey Burggraaff, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_bickt0agdtfbgs3s8ru6opkcsn